Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 55 | 2021 | 763 | 4.420 |
Why?
|
Epilepsy | 13 | 2023 | 395 | 3.760 |
Why?
|
Deep Brain Stimulation | 10 | 2018 | 54 | 3.550 |
Why?
|
Laser Therapy | 5 | 2023 | 142 | 3.350 |
Why?
|
Neurosurgical Procedures | 11 | 2021 | 213 | 3.090 |
Why?
|
Parkinson Disease | 10 | 2018 | 132 | 3.040 |
Why?
|
Epilepsy, Temporal Lobe | 13 | 2023 | 120 | 3.000 |
Why?
|
Subthalamic Nucleus | 8 | 2018 | 22 | 2.640 |
Why?
|
Glioma | 28 | 2021 | 285 | 2.440 |
Why?
|
Neuronavigation | 5 | 2020 | 21 | 2.430 |
Why?
|
Stereotaxic Techniques | 9 | 2020 | 69 | 2.200 |
Why?
|
Oligodendroglioma | 12 | 2011 | 45 | 2.060 |
Why?
|
Drug Resistant Epilepsy | 4 | 2023 | 40 | 1.840 |
Why?
|
Radiosurgery | 16 | 2020 | 272 | 1.680 |
Why?
|
Neurosurgery | 5 | 2020 | 84 | 1.660 |
Why?
|
Electroencephalography | 16 | 2023 | 707 | 1.450 |
Why?
|
Lennox Gastaut Syndrome | 2 | 2020 | 14 | 1.450 |
Why?
|
Corpus Callosum | 2 | 2020 | 56 | 1.430 |
Why?
|
Magnetic Resonance Imaging | 25 | 2023 | 3347 | 1.350 |
Why?
|
Pituitary Neoplasms | 3 | 2017 | 62 | 1.320 |
Why?
|
Humans | 122 | 2023 | 86281 | 0.970 |
Why?
|
Male | 68 | 2023 | 40860 | 0.940 |
Why?
|
Antiparkinson Agents | 2 | 2013 | 15 | 0.910 |
Why?
|
Seizures | 8 | 2023 | 293 | 0.860 |
Why?
|
Astrocytoma | 11 | 2010 | 82 | 0.860 |
Why?
|
Internal Capsule | 1 | 2021 | 4 | 0.840 |
Why?
|
Female | 69 | 2021 | 44405 | 0.820 |
Why?
|
Treatment Outcome | 28 | 2023 | 7949 | 0.820 |
Why?
|
Middle Aged | 48 | 2021 | 24957 | 0.810 |
Why?
|
Cross Infection | 2 | 2019 | 141 | 0.770 |
Why?
|
Neuroendoscopy | 1 | 2020 | 14 | 0.750 |
Why?
|
Ventriculostomy | 1 | 2020 | 26 | 0.740 |
Why?
|
Adult | 48 | 2021 | 25577 | 0.730 |
Why?
|
Moraxellaceae Infections | 1 | 2019 | 2 | 0.710 |
Why?
|
Basal Ganglia | 1 | 2019 | 42 | 0.700 |
Why?
|
Molecular Typing | 1 | 2019 | 17 | 0.700 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2021 | 157 | 0.700 |
Why?
|
Brain | 17 | 2022 | 2211 | 0.690 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 53 | 0.690 |
Why?
|
Terminology as Topic | 1 | 2020 | 217 | 0.680 |
Why?
|
Gait | 3 | 2015 | 80 | 0.670 |
Why?
|
Hippocampus | 7 | 2022 | 442 | 0.670 |
Why?
|
Blood-Brain Barrier | 7 | 2014 | 69 | 0.660 |
Why?
|
Capillaries | 3 | 2006 | 91 | 0.660 |
Why?
|
Disease Outbreaks | 1 | 2019 | 154 | 0.650 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 183 | 0.640 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2015 | 1305 | 0.630 |
Why?
|
Sclerosis | 1 | 2017 | 28 | 0.630 |
Why?
|
Electrodes, Implanted | 2 | 2016 | 171 | 0.620 |
Why?
|
Cerebral Hemorrhage | 4 | 2023 | 325 | 0.610 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2019 | 234 | 0.610 |
Why?
|
Craniopharyngioma | 1 | 2017 | 11 | 0.610 |
Why?
|
Levodopa | 2 | 2015 | 36 | 0.600 |
Why?
|
Anesthesia, General | 2 | 2018 | 114 | 0.600 |
Why?
|
Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 223 | 0.600 |
Why?
|
Gait Disorders, Neurologic | 2 | 2018 | 16 | 0.590 |
Why?
|
Imaging, Three-Dimensional | 4 | 2019 | 579 | 0.580 |
Why?
|
Vagus Nerve Stimulation | 1 | 2016 | 9 | 0.560 |
Why?
|
Hydrocephalus | 2 | 2020 | 101 | 0.550 |
Why?
|
Meningeal Neoplasms | 3 | 2011 | 61 | 0.550 |
Why?
|
Glioblastoma | 8 | 2003 | 254 | 0.550 |
Why?
|
Muscle Denervation | 1 | 2015 | 3 | 0.550 |
Why?
|
Torticollis | 1 | 2015 | 11 | 0.540 |
Why?
|
Meningioma | 2 | 2011 | 60 | 0.540 |
Why?
|
Aged | 35 | 2021 | 18353 | 0.540 |
Why?
|
Peripheral Nerves | 1 | 2015 | 36 | 0.540 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2015 | 19 | 0.540 |
Why?
|
Craniotomy | 4 | 2017 | 88 | 0.540 |
Why?
|
Chromosomes, Human, Pair 19 | 9 | 2011 | 59 | 0.530 |
Why?
|
Young Adult | 16 | 2021 | 5961 | 0.530 |
Why?
|
Epilepsies, Partial | 2 | 2013 | 40 | 0.520 |
Why?
|
Chromosomes, Human, Pair 1 | 8 | 2011 | 100 | 0.520 |
Why?
|
Postoperative Complications | 6 | 2019 | 2183 | 0.510 |
Why?
|
Intracranial Arteriovenous Malformations | 2 | 2014 | 104 | 0.500 |
Why?
|
Chorea | 1 | 2014 | 13 | 0.490 |
Why?
|
Deep Sedation | 1 | 2014 | 15 | 0.490 |
Why?
|
Scalp | 4 | 2022 | 72 | 0.480 |
Why?
|
Essential Tremor | 1 | 2013 | 6 | 0.480 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2007 | 1200 | 0.480 |
Why?
|
Stroke | 1 | 2023 | 959 | 0.470 |
Why?
|
Retrospective Studies | 19 | 2023 | 8431 | 0.470 |
Why?
|
Radio Waves | 1 | 2013 | 17 | 0.470 |
Why?
|
Electrocoagulation | 1 | 2013 | 21 | 0.470 |
Why?
|
Reoperation | 1 | 2016 | 589 | 0.470 |
Why?
|
Microsurgery | 2 | 2013 | 83 | 0.450 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 8 | 2015 | 90 | 0.450 |
Why?
|
Decompression, Surgical | 2 | 2020 | 87 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 17 | 2021 | 2594 | 0.440 |
Why?
|
Cerebellar Neoplasms | 4 | 2006 | 36 | 0.440 |
Why?
|
Dopamine Agonists | 1 | 2012 | 27 | 0.440 |
Why?
|
Capillary Permeability | 4 | 2006 | 130 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2006 | 2434 | 0.420 |
Why?
|
Carmustine | 2 | 2010 | 70 | 0.420 |
Why?
|
Central Nervous System Neoplasms | 2 | 2020 | 81 | 0.420 |
Why?
|
Lateral Ventricles | 1 | 2011 | 12 | 0.420 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2010 | 138 | 0.420 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2011 | 48 | 0.400 |
Why?
|
Regional Blood Flow | 6 | 2005 | 197 | 0.380 |
Why?
|
Spinal Cord Diseases | 2 | 2020 | 29 | 0.380 |
Why?
|
Cerebral Cortex | 5 | 2020 | 584 | 0.370 |
Why?
|
Sleep | 6 | 2022 | 440 | 0.370 |
Why?
|
Brachytherapy | 6 | 2005 | 119 | 0.370 |
Why?
|
Medulloblastoma | 2 | 2006 | 36 | 0.370 |
Why?
|
Survival Rate | 17 | 2013 | 1856 | 0.360 |
Why?
|
Genotype | 9 | 2019 | 1850 | 0.360 |
Why?
|
Endoscopy | 1 | 2013 | 331 | 0.360 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2010 | 138 | 0.340 |
Why?
|
Endothelial Growth Factors | 2 | 1999 | 55 | 0.330 |
Why?
|
Prospective Studies | 9 | 2018 | 4194 | 0.310 |
Why?
|
Cranial Irradiation | 6 | 2013 | 36 | 0.300 |
Why?
|
Adolescent | 15 | 2020 | 8968 | 0.300 |
Why?
|
Follow-Up Studies | 14 | 2020 | 3616 | 0.300 |
Why?
|
Prone Position | 2 | 2017 | 56 | 0.290 |
Why?
|
Child | 10 | 2021 | 6913 | 0.280 |
Why?
|
Cerebrovascular Circulation | 5 | 2010 | 212 | 0.280 |
Why?
|
Electrocorticography | 3 | 2020 | 37 | 0.270 |
Why?
|
Biopsy, Needle | 2 | 1999 | 234 | 0.270 |
Why?
|
Evidence-Based Medicine | 2 | 2004 | 429 | 0.260 |
Why?
|
Deglutition | 2 | 2015 | 73 | 0.260 |
Why?
|
Hematoma, Subdural | 1 | 2004 | 23 | 0.250 |
Why?
|
Combined Modality Therapy | 9 | 2013 | 1680 | 0.250 |
Why?
|
Beauty | 1 | 2023 | 8 | 0.240 |
Why?
|
Brain Abscess | 1 | 2003 | 8 | 0.240 |
Why?
|
Wakefulness | 3 | 2020 | 134 | 0.240 |
Why?
|
Carotid Artery, Internal | 1 | 2003 | 69 | 0.230 |
Why?
|
Lymphoma | 1 | 2005 | 262 | 0.230 |
Why?
|
Choline | 2 | 2005 | 23 | 0.220 |
Why?
|
Disease Progression | 6 | 2015 | 1531 | 0.220 |
Why?
|
Temporal Lobe | 3 | 2022 | 172 | 0.220 |
Why?
|
Memory Consolidation | 1 | 2022 | 14 | 0.220 |
Why?
|
Carotid Artery Diseases | 1 | 2003 | 97 | 0.220 |
Why?
|
Tomography, Spiral Computed | 1 | 2003 | 76 | 0.220 |
Why?
|
Intracranial Aneurysm | 1 | 2003 | 158 | 0.210 |
Why?
|
Cerebral Angiography | 1 | 2003 | 196 | 0.210 |
Why?
|
Prognosis | 10 | 2016 | 3669 | 0.210 |
Why?
|
Somatosensory Cortex | 1 | 2023 | 129 | 0.210 |
Why?
|
Gamma Rays | 1 | 2001 | 72 | 0.210 |
Why?
|
Telomerase | 1 | 2021 | 55 | 0.200 |
Why?
|
Motor Cortex | 1 | 2023 | 195 | 0.200 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 67 | 0.200 |
Why?
|
Acetylcholine | 1 | 2001 | 176 | 0.200 |
Why?
|
Gliosarcoma | 1 | 2000 | 7 | 0.200 |
Why?
|
Prevalence | 3 | 2020 | 1239 | 0.190 |
Why?
|
Trauma, Nervous System | 1 | 2020 | 6 | 0.190 |
Why?
|
Blood Volume | 2 | 2006 | 51 | 0.190 |
Why?
|
Embolization, Therapeutic | 1 | 2003 | 238 | 0.190 |
Why?
|
Psychosurgery | 1 | 2020 | 13 | 0.190 |
Why?
|
Traumatology | 1 | 2020 | 27 | 0.190 |
Why?
|
Encephalitis | 2 | 2018 | 104 | 0.190 |
Why?
|
Phenotype | 3 | 2019 | 2375 | 0.190 |
Why?
|
Semantics | 1 | 2020 | 50 | 0.190 |
Why?
|
Third Ventricle | 1 | 2020 | 11 | 0.190 |
Why?
|
Spinal Diseases | 1 | 2020 | 44 | 0.190 |
Why?
|
Theta Rhythm | 1 | 2020 | 27 | 0.190 |
Why?
|
Surgical Oncology | 1 | 2020 | 27 | 0.190 |
Why?
|
Skull Base | 1 | 2020 | 47 | 0.190 |
Why?
|
Neurofibromatosis 1 | 1 | 2020 | 36 | 0.180 |
Why?
|
Dura Mater | 1 | 2020 | 44 | 0.180 |
Why?
|
Genetic Therapy | 3 | 2013 | 342 | 0.180 |
Why?
|
Neurology | 1 | 2020 | 69 | 0.180 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2020 | 85 | 0.180 |
Why?
|
Neovascularization, Pathologic | 2 | 1999 | 352 | 0.180 |
Why?
|
Staphylococcal Infections | 2 | 2017 | 255 | 0.180 |
Why?
|
Neurological Rehabilitation | 1 | 2019 | 1 | 0.180 |
Why?
|
Cerebrovascular Disorders | 1 | 2020 | 142 | 0.180 |
Why?
|
Lasers | 3 | 2023 | 104 | 0.180 |
Why?
|
Videotape Recording | 1 | 1999 | 47 | 0.180 |
Why?
|
Tumor Cells, Cultured | 2 | 2000 | 1040 | 0.170 |
Why?
|
Vascular Surgical Procedures | 1 | 2020 | 148 | 0.170 |
Why?
|
Loss of Heterozygosity | 3 | 2006 | 85 | 0.170 |
Why?
|
Lymphokines | 1 | 1999 | 76 | 0.170 |
Why?
|
Biopsy | 7 | 2007 | 1160 | 0.170 |
Why?
|
Thrombolytic Therapy | 1 | 2021 | 220 | 0.170 |
Why?
|
Language | 1 | 2020 | 151 | 0.170 |
Why?
|
Bone Transplantation | 2 | 2014 | 64 | 0.170 |
Why?
|
Brain Waves | 1 | 2019 | 32 | 0.170 |
Why?
|
Implantable Neurostimulators | 1 | 2018 | 12 | 0.170 |
Why?
|
Risk Assessment | 1 | 2006 | 2253 | 0.170 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 57 | 0.170 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2019 | 136 | 0.160 |
Why?
|
Intracranial Pressure | 2 | 2017 | 77 | 0.160 |
Why?
|
Cell Survival | 1 | 2000 | 966 | 0.160 |
Why?
|
Cognitive Dysfunction | 1 | 2020 | 132 | 0.160 |
Why?
|
Limbic Encephalitis | 1 | 2018 | 11 | 0.160 |
Why?
|
Glutamate Decarboxylase | 1 | 2018 | 32 | 0.160 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 502 | 0.160 |
Why?
|
Brain Mapping | 3 | 2020 | 547 | 0.160 |
Why?
|
Brain Edema | 2 | 1998 | 50 | 0.160 |
Why?
|
General Surgery | 1 | 2020 | 228 | 0.160 |
Why?
|
Infection Control | 1 | 2019 | 115 | 0.160 |
Why?
|
Carrier State | 1 | 2017 | 39 | 0.160 |
Why?
|
Carrier Proteins | 1 | 2001 | 672 | 0.160 |
Why?
|
Thymidine Kinase | 2 | 2013 | 30 | 0.160 |
Why?
|
Blood Vessels | 1 | 1997 | 94 | 0.150 |
Why?
|
Ganciclovir | 2 | 2013 | 49 | 0.150 |
Why?
|
Death, Sudden | 1 | 2017 | 40 | 0.150 |
Why?
|
Alleles | 3 | 2006 | 1127 | 0.150 |
Why?
|
Dexamethasone | 2 | 1998 | 326 | 0.150 |
Why?
|
Receptors, GABA-A | 1 | 1997 | 32 | 0.150 |
Why?
|
Intracranial Hypertension | 1 | 2017 | 48 | 0.150 |
Why?
|
Multimodal Imaging | 1 | 2017 | 110 | 0.150 |
Why?
|
Delta Rhythm | 1 | 2016 | 19 | 0.150 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 73 | 0.150 |
Why?
|
Databases, Factual | 2 | 2021 | 808 | 0.150 |
Why?
|
Lomustine | 2 | 2006 | 26 | 0.150 |
Why?
|
Procarbazine | 2 | 2006 | 40 | 0.150 |
Why?
|
Nerve Net | 1 | 2020 | 366 | 0.150 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2016 | 9 | 0.140 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1997 | 78 | 0.140 |
Why?
|
Deglutition Disorders | 1 | 2018 | 115 | 0.140 |
Why?
|
Vincristine | 2 | 2006 | 111 | 0.140 |
Why?
|
Neurons | 2 | 2023 | 1545 | 0.140 |
Why?
|
Pediatrics | 1 | 2020 | 344 | 0.140 |
Why?
|
Orthopedic Procedures | 1 | 2017 | 128 | 0.140 |
Why?
|
Epilepsy, Generalized | 1 | 2016 | 37 | 0.140 |
Why?
|
Antibodies | 1 | 2018 | 349 | 0.140 |
Why?
|
Chromosomes, Human, Pair 10 | 3 | 2005 | 47 | 0.140 |
Why?
|
Bone Matrix | 2 | 2014 | 18 | 0.140 |
Why?
|
Brain Injuries, Traumatic | 1 | 2017 | 86 | 0.130 |
Why?
|
Neoplasm Proteins | 1 | 1999 | 532 | 0.130 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2005 | 110 | 0.130 |
Why?
|
Neoplasm, Residual | 2 | 1995 | 162 | 0.130 |
Why?
|
Energy Metabolism | 1 | 1997 | 271 | 0.130 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 30 | 0.120 |
Why?
|
Radiation Injuries | 1 | 2015 | 155 | 0.120 |
Why?
|
Skull Fractures | 1 | 2014 | 24 | 0.120 |
Why?
|
Mental Disorders | 1 | 2018 | 371 | 0.120 |
Why?
|
Frontal Bone | 1 | 2014 | 16 | 0.120 |
Why?
|
Parietal Bone | 1 | 2014 | 20 | 0.120 |
Why?
|
Gold | 1 | 2014 | 41 | 0.120 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 111 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1995 | 150 | 0.120 |
Why?
|
Doxorubicin | 1 | 2014 | 289 | 0.120 |
Why?
|
Extracellular Space | 1 | 1994 | 90 | 0.120 |
Why?
|
Temporal Bone | 1 | 2014 | 66 | 0.120 |
Why?
|
Risk Factors | 6 | 2020 | 5397 | 0.120 |
Why?
|
Cohort Studies | 2 | 2016 | 2759 | 0.110 |
Why?
|
Dogs | 6 | 1995 | 684 | 0.110 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 461 | 0.110 |
Why?
|
Hypokinesia | 1 | 2012 | 3 | 0.110 |
Why?
|
Blood Glucose | 1 | 1997 | 873 | 0.110 |
Why?
|
Adenoviridae | 1 | 2013 | 345 | 0.110 |
Why?
|
Hemorrhage | 1 | 2014 | 265 | 0.100 |
Why?
|
Animals | 16 | 2014 | 26518 | 0.100 |
Why?
|
Mannitol | 2 | 1989 | 49 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2011 | 291 | 0.100 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2001 | 188 | 0.100 |
Why?
|
Syndrome | 1 | 2011 | 446 | 0.100 |
Why?
|
Contrast Media | 3 | 2014 | 1076 | 0.090 |
Why?
|
Thallium | 1 | 2010 | 8 | 0.090 |
Why?
|
Radiotherapy Dosage | 5 | 2011 | 468 | 0.090 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2010 | 20 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2011 | 1196 | 0.090 |
Why?
|
Karnofsky Performance Status | 1 | 2010 | 40 | 0.090 |
Why?
|
Injections, Intramuscular | 1 | 2010 | 62 | 0.090 |
Why?
|
Saline Solution, Hypertonic | 1 | 1989 | 24 | 0.090 |
Why?
|
Iodine Radioisotopes | 3 | 2004 | 134 | 0.090 |
Why?
|
Sodium Chloride | 1 | 1989 | 86 | 0.090 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 1989 | 32 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2013 | 508 | 0.090 |
Why?
|
Necrosis | 3 | 2015 | 204 | 0.080 |
Why?
|
Video Recording | 2 | 2020 | 190 | 0.080 |
Why?
|
Cognition | 1 | 2013 | 570 | 0.080 |
Why?
|
Neoplasm Metastasis | 1 | 1993 | 1056 | 0.080 |
Why?
|
Drug Delivery Systems | 2 | 2005 | 178 | 0.080 |
Why?
|
Allelic Imbalance | 4 | 2011 | 20 | 0.080 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 1987 | 4 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2006 | 526 | 0.080 |
Why?
|
Time Factors | 4 | 2021 | 5198 | 0.080 |
Why?
|
Down-Regulation | 3 | 2007 | 504 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2006 | 2267 | 0.080 |
Why?
|
Pituitary Irradiation | 1 | 2007 | 2 | 0.080 |
Why?
|
Hypophysectomy | 1 | 2007 | 27 | 0.080 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2007 | 58 | 0.070 |
Why?
|
Optic Nerve | 1 | 2007 | 35 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2005 | 318 | 0.070 |
Why?
|
Ki-67 Antigen | 1 | 2007 | 64 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2010 | 1203 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 850 | 0.070 |
Why?
|
Pituitary Gland | 1 | 2007 | 117 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2021 | 6481 | 0.070 |
Why?
|
ADAM Proteins | 1 | 2006 | 11 | 0.070 |
Why?
|
Cell Adhesion Molecules | 1 | 2007 | 163 | 0.070 |
Why?
|
Promoter Regions, Genetic | 3 | 2021 | 937 | 0.070 |
Why?
|
Avian Sarcoma Viruses | 3 | 1995 | 7 | 0.070 |
Why?
|
Data Interpretation, Statistical | 2 | 2004 | 297 | 0.070 |
Why?
|
Biomarkers, Tumor | 2 | 2003 | 1461 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2007 | 294 | 0.070 |
Why?
|
Iopamidol | 1 | 2005 | 10 | 0.070 |
Why?
|
Adenosine | 1 | 1987 | 224 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2007 | 551 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2010 | 1932 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2018 | 1822 | 0.060 |
Why?
|
Hypothalamic Diseases | 1 | 2004 | 2 | 0.060 |
Why?
|
Genetic Testing | 2 | 2005 | 535 | 0.060 |
Why?
|
Quality Control | 1 | 2004 | 117 | 0.060 |
Why?
|
Neurocytoma | 1 | 2003 | 3 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2021 | 1671 | 0.060 |
Why?
|
Hamartoma | 1 | 2004 | 31 | 0.060 |
Why?
|
Lipoma | 1 | 2003 | 25 | 0.060 |
Why?
|
Research Design | 3 | 2004 | 594 | 0.060 |
Why?
|
Neurologic Examination | 3 | 1999 | 118 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2006 | 309 | 0.060 |
Why?
|
Genes, p53 | 1 | 2003 | 109 | 0.060 |
Why?
|
Microsatellite Repeats | 1 | 2003 | 141 | 0.060 |
Why?
|
Amplifiers, Electronic | 1 | 2022 | 6 | 0.060 |
Why?
|
Interleukin-12 | 1 | 2003 | 108 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2005 | 380 | 0.060 |
Why?
|
Amino Acids | 1 | 2003 | 252 | 0.060 |
Why?
|
Entropy | 1 | 2002 | 38 | 0.060 |
Why?
|
Electric Stimulation | 1 | 2023 | 347 | 0.060 |
Why?
|
Hand | 1 | 2023 | 130 | 0.060 |
Why?
|
Spatial Memory | 1 | 2022 | 27 | 0.050 |
Why?
|
Angiography, Digital Subtraction | 1 | 2003 | 91 | 0.050 |
Why?
|
Genetic Markers | 1 | 2003 | 476 | 0.050 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2001 | 10 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2006 | 407 | 0.050 |
Why?
|
Hemicholinium 3 | 1 | 2001 | 1 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2005 | 480 | 0.050 |
Why?
|
Neurotransmitter Uptake Inhibitors | 1 | 2001 | 4 | 0.050 |
Why?
|
Tritium | 1 | 2001 | 133 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 3608 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2006 | 1801 | 0.050 |
Why?
|
Lateral Thalamic Nuclei | 1 | 2001 | 4 | 0.050 |
Why?
|
Postoperative Period | 1 | 2022 | 303 | 0.050 |
Why?
|
Mouth Neoplasms | 1 | 2003 | 194 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 877 | 0.050 |
Why?
|
Mutation | 2 | 2021 | 3952 | 0.050 |
Why?
|
Organ Culture Techniques | 1 | 2001 | 134 | 0.050 |
Why?
|
Movement | 1 | 2023 | 299 | 0.050 |
Why?
|
ErbB Receptors | 2 | 2021 | 485 | 0.050 |
Why?
|
Tourette Syndrome | 1 | 2001 | 25 | 0.050 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2001 | 126 | 0.050 |
Why?
|
Mental Recall | 1 | 2022 | 158 | 0.050 |
Why?
|
Interphase | 1 | 2000 | 34 | 0.050 |
Why?
|
Regression Analysis | 3 | 2003 | 595 | 0.050 |
Why?
|
Sarcoma, Experimental | 2 | 1995 | 53 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 169 | 0.050 |
Why?
|
Chronic Disease | 1 | 2004 | 968 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2003 | 751 | 0.050 |
Why?
|
Biological Transport | 4 | 1991 | 396 | 0.050 |
Why?
|
Mandible | 1 | 2001 | 119 | 0.050 |
Why?
|
Rabbits | 1 | 2001 | 636 | 0.050 |
Why?
|
Dilatation, Pathologic | 1 | 2020 | 54 | 0.050 |
Why?
|
Conservative Treatment | 1 | 2020 | 20 | 0.050 |
Why?
|
Transplantation, Heterologous | 3 | 2001 | 363 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2011 | 155 | 0.050 |
Why?
|
Transforming Growth Factor beta | 1 | 2001 | 298 | 0.040 |
Why?
|
Anticonvulsants | 1 | 2020 | 126 | 0.040 |
Why?
|
Therapy, Computer-Assisted | 1 | 1999 | 17 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2011 | 369 | 0.040 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1999 | 56 | 0.040 |
Why?
|
Pneumonia | 1 | 2020 | 178 | 0.040 |
Why?
|
Neurophysiological Monitoring | 1 | 2018 | 11 | 0.040 |
Why?
|
Neoplasm Transplantation | 3 | 1991 | 391 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2699 | 0.040 |
Why?
|
Xenon | 1 | 1998 | 7 | 0.040 |
Why?
|
Supratentorial Neoplasms | 1 | 1998 | 10 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2021 | 294 | 0.040 |
Why?
|
Patient Discharge | 1 | 2021 | 296 | 0.040 |
Why?
|
Electrodes | 1 | 2018 | 78 | 0.040 |
Why?
|
Specimen Handling | 1 | 1999 | 98 | 0.040 |
Why?
|
Rats | 4 | 1991 | 3984 | 0.040 |
Why?
|
Groin | 1 | 2017 | 7 | 0.040 |
Why?
|
Polysomnography | 1 | 2018 | 150 | 0.040 |
Why?
|
Carboxy-Lyases | 1 | 2018 | 22 | 0.040 |
Why?
|
Barbiturates | 1 | 2017 | 12 | 0.040 |
Why?
|
Germany | 1 | 2017 | 72 | 0.040 |
Why?
|
Immunotherapy | 1 | 2003 | 627 | 0.040 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 464 | 0.040 |
Why?
|
Pharynx | 1 | 2017 | 45 | 0.040 |
Why?
|
Aminoisobutyric Acids | 2 | 1987 | 4 | 0.040 |
Why?
|
Decompressive Craniectomy | 1 | 2017 | 18 | 0.040 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 66 | 0.040 |
Why?
|
Blood Flow Velocity | 2 | 1998 | 197 | 0.040 |
Why?
|
Functional Laterality | 1 | 2018 | 201 | 0.040 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 93 | 0.040 |
Why?
|
Antimetabolites | 1 | 1997 | 24 | 0.040 |
Why?
|
Nasal Cavity | 1 | 2017 | 91 | 0.040 |
Why?
|
Posture | 1 | 2017 | 125 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2018 | 399 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2015 | 1562 | 0.040 |
Why?
|
Tomography, Emission-Computed | 1 | 1997 | 103 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 1999 | 927 | 0.040 |
Why?
|
Autoantibodies | 1 | 2018 | 267 | 0.040 |
Why?
|
Personality | 1 | 2018 | 133 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2003 | 1075 | 0.040 |
Why?
|
Bias | 1 | 1997 | 127 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 268 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 1998 | 339 | 0.030 |
Why?
|
Methylation | 2 | 2007 | 251 | 0.030 |
Why?
|
Age of Onset | 1 | 2016 | 306 | 0.030 |
Why?
|
Spin Labels | 1 | 2015 | 102 | 0.030 |
Why?
|
Potassium Channels, Voltage-Gated | 1 | 2016 | 122 | 0.030 |
Why?
|
Barium Sulfate | 1 | 2014 | 43 | 0.030 |
Why?
|
Mathematics | 1 | 1995 | 190 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 1999 | 1752 | 0.030 |
Why?
|
Models, Cardiovascular | 1 | 1995 | 98 | 0.030 |
Why?
|
Nimustine | 1 | 1994 | 1 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 241 | 0.030 |
Why?
|
Apoptosis | 1 | 2000 | 1678 | 0.030 |
Why?
|
Drug Implants | 2 | 2004 | 34 | 0.030 |
Why?
|
Radiation Dosage | 2 | 1993 | 227 | 0.030 |
Why?
|
Infant | 1 | 2020 | 3036 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 329 | 0.030 |
Why?
|
Interferons | 1 | 1994 | 132 | 0.030 |
Why?
|
Radiography | 2 | 2011 | 812 | 0.030 |
Why?
|
Anaplasia | 1 | 1993 | 5 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 1381 | 0.030 |
Why?
|
Patient Selection | 1 | 1997 | 685 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 1610 | 0.030 |
Why?
|
Skull | 1 | 2014 | 248 | 0.030 |
Why?
|
Kinetics | 1 | 1995 | 1513 | 0.030 |
Why?
|
Biomarkers | 1 | 2018 | 1709 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2013 | 356 | 0.030 |
Why?
|
Incidence | 1 | 2016 | 1568 | 0.030 |
Why?
|
Rats, Inbred Strains | 2 | 1991 | 312 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 37 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 2421 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 272 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2014 | 1796 | 0.020 |
Why?
|
Genetic Vectors | 2 | 2003 | 438 | 0.020 |
Why?
|
Quality of Life | 2 | 1995 | 1575 | 0.020 |
Why?
|
Osmosis | 1 | 1987 | 6 | 0.020 |
Why?
|
Ethylnitrosourea | 1 | 1987 | 30 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
Mice | 2 | 2014 | 11313 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 307 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2007 | 50 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 87 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1987 | 429 | 0.020 |
Why?
|
ADAMTS Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2007 | 393 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 589 | 0.020 |
Why?
|
Alternative Splicing | 1 | 2007 | 201 | 0.020 |
Why?
|
United States | 1 | 2018 | 6637 | 0.020 |
Why?
|
Gene Expression | 1 | 2010 | 1281 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2006 | 2351 | 0.020 |
Why?
|
Lactic Acid | 1 | 2005 | 90 | 0.020 |
Why?
|
Exons | 1 | 2007 | 450 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1989 | 397 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 1987 | 1047 | 0.020 |
Why?
|
Models, Biological | 1 | 1991 | 1748 | 0.020 |
Why?
|
Blotting, Western | 1 | 2006 | 781 | 0.020 |
Why?
|
Semliki forest virus | 1 | 2003 | 8 | 0.010 |
Why?
|
Mandibular Neoplasms | 1 | 2003 | 24 | 0.010 |
Why?
|
Lipids | 1 | 2005 | 269 | 0.010 |
Why?
|
Capsules | 1 | 2003 | 38 | 0.010 |
Why?
|
Liposomes | 1 | 2003 | 91 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2006 | 388 | 0.010 |
Why?
|
Binding Sites | 1 | 2006 | 1098 | 0.010 |
Why?
|
Drug Resistance | 1 | 2004 | 256 | 0.010 |
Why?
|
Internationality | 1 | 2003 | 69 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2007 | 2062 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2003 | 116 | 0.010 |
Why?
|
Drug Carriers | 1 | 2003 | 81 | 0.010 |
Why?
|
Microradiography | 1 | 2001 | 2 | 0.010 |
Why?
|
Collagen | 1 | 2003 | 268 | 0.010 |
Why?
|
Bone Substitutes | 1 | 2001 | 9 | 0.010 |
Why?
|
Bone Morphogenetic Protein 7 | 1 | 2001 | 11 | 0.010 |
Why?
|
Swine, Miniature | 1 | 2001 | 51 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2007 | 3029 | 0.010 |
Why?
|
Minerals | 1 | 2001 | 22 | 0.010 |
Why?
|
Bone Plates | 1 | 2001 | 23 | 0.010 |
Why?
|
Virus Replication | 1 | 2003 | 319 | 0.010 |
Why?
|
Bone Screws | 1 | 2001 | 43 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 2003 | 193 | 0.010 |
Why?
|
Tics | 1 | 2001 | 4 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 1987 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2001 | 179 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2003 | 857 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2001 | 264 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 1536 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2001 | 242 | 0.010 |
Why?
|
Swine | 1 | 2001 | 554 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2001 | 424 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2006 | 1975 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2001 | 1014 | 0.010 |
Why?
|
Surgical Flaps | 1 | 2001 | 238 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1999 | 274 | 0.010 |
Why?
|
Dominance, Cerebral | 1 | 1998 | 66 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2001 | 448 | 0.010 |
Why?
|
Decision Making | 1 | 2004 | 641 | 0.010 |
Why?
|
Graft Survival | 1 | 2001 | 883 | 0.010 |
Why?
|
Gene Deletion | 1 | 1999 | 328 | 0.010 |
Why?
|
Clinical Protocols | 1 | 1997 | 155 | 0.010 |
Why?
|
Simplexvirus | 1 | 1997 | 151 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 1995 | 173 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 1995 | 155 | 0.010 |
Why?
|
Palliative Care | 1 | 1994 | 256 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1994 | 468 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 1995 | 997 | 0.010 |
Why?
|
Iothalamate Meglumine | 1 | 1991 | 5 | 0.010 |
Why?
|
Autoradiography | 1 | 1991 | 69 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 1991 | 156 | 0.010 |
Why?
|
Equipment Design | 1 | 1991 | 405 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 1991 | 269 | 0.010 |
Why?
|
Yttrium | 1 | 1983 | 3 | 0.000 |
Why?
|
Iridium | 1 | 1983 | 3 | 0.000 |
Why?
|
Radioisotopes | 1 | 1983 | 45 | 0.000 |
Why?
|
Radiation Injuries, Experimental | 1 | 1983 | 41 | 0.000 |
Why?
|
Edema | 1 | 1983 | 70 | 0.000 |
Why?
|